Patent ID: 11896597
Assignee: DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating an ErbB associated disease in a subject, comprising administering to the subject about 50 mg to about 500 mg per day of (R)—N-(5-(4-(5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)phenylamino)pyrimidin-2-ylamino)-2-(3-(dimethylamino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamide, or a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, wherein the ErbB associated disease is lung cancer.